PEG Grafeel 6mg Injection

About

PEG Grafeel 6mg Injection is a pegylated form of recombinant human granulocyte colony-stimulating factor (G-CSF). It functions by stimulating the production, maturation, and release of neutrophils from the bone marrow. Neutrophils are a type of white blood cell crucial for fighting bacterial and fungal infections. The pegylation process extends the half-life of filgrastim, allowing for a single dose per chemotherapy cycle, which simplifies administration and improves patient compliance. This medication is primarily used to reduce the incidence of febrile neutropenia, a serious complication characterized by fever and a dangerously low neutrophil count, in patients undergoing myelosuppressive chemotherapy for non-myeloid malignancies. By preventing severe neutropenia, PEG Grafeel helps to decrease the risk of life-threatening infections.

Uses

• Prevention of febrile neutropenia
• Chemotherapy-induced neutropenia
• Bone marrow transplantation support
• Mobilization of hematopoietic stem cells

Directions For Use

Administer subcutaneously once per chemotherapy cycle, at least 24 hours after chemotherapy. Do not administer within 14 days before the next chemotherapy dose.

Benefits

• Reduces incidence of febrile neutropenia.
• Decreases risk of infection during chemotherapy.
• Single dose per chemotherapy cycle.
• Stimulates neutrophil production effectively.
• Improves patient safety during chemotherapy.
• Supports bone marrow recovery.

Side Effects

• Bone pain
• Myalgia (muscle pain)
• Headache
• Nausea
• Fatigue
• Injection site reactions
• Splenic rupture (rare but serious)
• Acute respiratory distress syndrome (ARDS) (rare)
• Allergic reactions
• Glomerulonephritis (rare)
• Leukocytosis (high white blood cell count)
• Thrombocytopenia (low platelet count)

Safety Measures

• Alcohol - No specific interaction with alcohol is known, but general health recommendations to limit alcohol intake apply, especially during cancer treatment.
• Pregnancy - Use only if clearly needed; potential risks to the fetus are not fully established, and benefits must outweigh potential risks.
• Breastfeeding - Exercise caution; it is unknown if PEG Grafeel is excreted in human milk, and potential effects on the infant are not known.
• Liver - No specific dose adjustment needed for liver impairment. Monitor liver function as part of general patient care.
• Kidney - No specific dose adjustment needed for renal impairment. Monitor kidney function as part of general patient care.
• Lung - Monitor for pulmonary symptoms; rare cases of ARDS and interstitial lung disease have been reported. Discontinue if pulmonary toxicity occurs.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.